You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Type 2 Issues Articles
Popular Type 2 Issues Articles
Highly Recommended Type 2 Issues Articles
Send a link to this page to your friends and colleagues.
A 24-week study compared the effectiveness and safety of Galvus (vildagliptin), a DPP-4 inhibitor, with Avandia (rosiglitazone), a thiazolidinedione, in a double-blind, randomized, controlled, multi-center study. Both drugs had similar effects on A1c’s: Galvus reduced A1c by 1.1 %, and Avandia reduced A1c by 1. 3%. Most notably, patients did not gain weight with Galvus, but gained an average of 3.4 pounds with Avandia.
Galvus, made by Novartis, is in the same class as sitagliptin (Januvia), another DPP-4 inhibitor. Unlike Januvia, Galvus has not been approved by the FDA. FDA approval was expected by November 2006, but then the FDA asked for more data about studies linking Galvus to skin lesions in monkeys. In late February 2007, the FDA asked for a clinical study in patients with kidney impairment. It now looks as if Galvus will not be approved by the FDA for a year or more.
Sources: Diabetes Care
Associated Press
Forbes.com
Categories: A1c Test, Diabetes, Diabetes, Type 2 Issues, Type 2 Medications
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.

Comments
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...